284 related articles for article (PubMed ID: 15452897)
41. The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis.
van de Molengraft FJ; Vooijs GP
Acta Cytol; 1988; 32(2):183-7. PubMed ID: 3348059
[TBL] [Abstract][Full Text] [Related]
42. Diagnosis and categorization of malignant effusions: A 6-year review from a single academic institution.
Lew M; Cantley R; Heider A; Jing X
Diagn Cytopathol; 2021 May; 49(5):615-621. PubMed ID: 32275354
[TBL] [Abstract][Full Text] [Related]
43. Cytologic diagnosis of metastatic sarcoma in effusions.
Longatto-Filho A; Bisi H; Bortolan J; Granja NV; Lombardo V
Acta Cytol; 2003; 47(2):317-8. PubMed ID: 12685210
[No Abstract] [Full Text] [Related]
44. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
Davidson B; Xi Z; Klokk TI; Tropé CG; Dørum A; Scheistrøen M; Saatcioglu F
Am J Clin Pathol; 2005 Mar; 123(3):360-8. PubMed ID: 15716231
[TBL] [Abstract][Full Text] [Related]
45. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
46. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
[TBL] [Abstract][Full Text] [Related]
47. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
48. New determinates of disease progression and outcome in metastatic ovarian carcinoma.
Davidson B; Reich R; Trope CG; Wang TL; Shih IeM
Histol Histopathol; 2010 Dec; 25(12):1591-609. PubMed ID: 20886439
[TBL] [Abstract][Full Text] [Related]
49. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
Ciampa A; Fanger G; Khan A; Rock KL; Xu B
Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
[TBL] [Abstract][Full Text] [Related]
50. Adult granulosa cell tumor presenting as metastases to the pleural and peritoneal cavity.
Gupta N; Rajwanshi A; Dey P; Suri V
Diagn Cytopathol; 2012 Oct; 40(10):912-5. PubMed ID: 21618710
[TBL] [Abstract][Full Text] [Related]
51. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
52. Role of DNA flow cytometry and immunocytochemical analysis in diagnosis of malignant effusions.
Kundu R; Handa U; Mohan H
Diagn Cytopathol; 2012 Oct; 40(10):887-92. PubMed ID: 21485027
[TBL] [Abstract][Full Text] [Related]
53. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
Davidson B; Shafat I; Risberg B; Ilan N; Trope' CG; Vlodavsky I; Reich R
Gynecol Oncol; 2007 Feb; 104(2):311-9. PubMed ID: 17030350
[TBL] [Abstract][Full Text] [Related]
54. Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
Konstantinovsky S; Nielsen S; Vyberg M; Kvalheim G; Nesland JM; Reich R; Davidson B
Breast Cancer Res Treat; 2005 Nov; 94(1):71-80. PubMed ID: 16142438
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters.
Dong HP; Holth A; Kleinberg L; Ruud MG; Elstrand MB; Tropé CG; Davidson B; Risberg B
Am J Clin Pathol; 2009 Nov; 132(5):756-62. PubMed ID: 19846818
[TBL] [Abstract][Full Text] [Related]
56. Survival of patients with malignancy-associated effusions.
van de Molengraft FJ; Vooijs GP
Acta Cytol; 1989; 33(6):911-6. PubMed ID: 2588923
[TBL] [Abstract][Full Text] [Related]
57. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
[TBL] [Abstract][Full Text] [Related]
58. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
59. Expression of seprase in effusions from patients with epithelial ovarian carcinoma.
Zhang MZ; Qiao YH; Nesland JM; Trope C; Kennedy A; Chen WT; Suo ZH
Chin Med J (Engl); 2007 Apr; 120(8):663-8. PubMed ID: 17517181
[TBL] [Abstract][Full Text] [Related]
60. The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer. Part III: diagnosis and management of malignant pleural effusions.
Yoneda KY; Mathur PN; Gasparini S
Clin Lung Cancer; 2007 Nov; 8(9):535-47. PubMed ID: 18186958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
